摘要
目的:分析观察赛尼哌用于肾移植免疫诱导的临床疗效及其安全性和耐受性。方法:将同期进行的68例肾移植病例分为两组,一组在术前和术后使用了赛尼哌作免疫诱导,另一组使用的是常规的三联免疫治疗,比较两组6个月内的临床情况。结果:使用赛尼哌的患者肾功能恢复和在1个月后明显优于对照组,排斥反应发生率显著降低(P<0.05),而不良反应和其他感染的发生率两组无统计学差异。结论:赛尼哌用于肾移植的免疫诱导治疗,可以预防和减少急性排斥反应的发生,安全性和耐受性好。赛尼哌、低剂量钙调素抑制剂、皮质激素三联治疗方案是对肾移植患者有益的新选择。
OBJECTIVE： To observe clinical curative effect, the safety and tolerance of zenapax used for immunity induction of renal transplantation. METHODS： 68 patients with renal transplantation were divided into 2 groups. One group of patients used zenapax as immunity induction before and after operation, another group of patients used routine trigeminy immunotherapy. Clinical curative effect of two groups within nine months was compared. RESULTS： Renal functional recovery in patients using zenapax for one month was obviously better than that of control group. Reject reaction incidence greatly decreased（ P 〈 0.05）, but there was no statistic difference between two groups in incidence of adverse reactions and other infections. CONCLUSION： Zenapax used for immunity induction of renal transplantation can prevent and reduce the occurrence of acute reject reaction, it has safety and good tolerance. Trigeminy therapeutic regimen of zenapax, low dose calmodulin inhibitors and adrenal cortex hormone has been the new benefit choice for patients with renal transplantation.
出处
《中国医院用药评价与分析》
2005年第6期340-341,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
赛尼哌
肾移植
急性排斥反应
免疫诱导
zenapax
renal transplantation
acute reject reaction
immunity induction
